12:00 AM
Oct 08, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Botox onabotulinumtoxinA regulatory update

Allergan said the U.K.'s Medicines and Healthcare Products Regulatory Agency (MHRA) approved Botox onabotulinumtoxinA to manage urinary incontinence in adult patients with neurogenic detrusor overactivity (NDO) due to subcervical spinal cord injury (SCI) or multiple sclerosis (MS) who are not adequately managed with...

Read the full 192 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >